Dilemmas of a vitalizing vaccine market: lessons from the MMR vaccine/autism debate
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artikel |
| Sprache: | English |
| Veröffentlicht: |
2011
|
| Schlagworte: | |
| ISSN: | 0269-8897 |
Internformat
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV037264654 | ||
| 003 | DE-604 | ||
| 005 | 20180830 | ||
| 007 | t | ||
| 008 | 110304s2011 |||| 00||| eng d | ||
| 035 | |a (OCoLC)907788528 | ||
| 035 | |a (DE-599)BVBBV037264654 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-210 | ||
| 100 | 1 | |a Bragesjö, Fredrik |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Dilemmas of a vitalizing vaccine market |b lessons from the MMR vaccine/autism debate |c Fredrik Bragesjö and Margareta Hallberg |
| 264 | 1 | |c 2011 | |
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 0 | 7 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Impfung |0 (DE-588)4026656-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Gesundheitspolitik |0 (DE-588)4113743-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Impfschaden |0 (DE-588)4161405-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Impfstoff |0 (DE-588)4026655-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Gesellschaft |0 (DE-588)4020588-5 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Impfung |0 (DE-588)4026656-4 |D s |
| 689 | 0 | 1 | |a Impfstoff |0 (DE-588)4026655-2 |D s |
| 689 | 0 | 2 | |a Impfschaden |0 (DE-588)4161405-7 |D s |
| 689 | 0 | 3 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |D s |
| 689 | 0 | 4 | |a Gesundheitspolitik |0 (DE-588)4113743-7 |D s |
| 689 | 0 | 5 | |a Gesellschaft |0 (DE-588)4020588-5 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Hallberg, Margareta |e Verfasser |4 aut | |
| 773 | 1 | 8 | |g volume:24 |g number:1 |g year:2011 |g pages:107-125 |
| 773 | 0 | 8 | |t Science in context |d Cambridge |g 24 (2011),1, S. [107] - 125 |w (DE-604)BV002714438 |x 0269-8897 |o (DE-600)284093-5 |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-021177722 | ||
| 941 | |b 24 |h 1 |j 2011 |s 107-125 | ||
Datensatz im Suchindex
| _version_ | 1804143885291618304 |
|---|---|
| any_adam_object | |
| article_link | (DE-604)BV002714438 |
| author | Bragesjö, Fredrik Hallberg, Margareta |
| author_facet | Bragesjö, Fredrik Hallberg, Margareta |
| author_role | aut aut |
| author_sort | Bragesjö, Fredrik |
| author_variant | f b fb m h mh |
| building | Verbundindex |
| bvnumber | BV037264654 |
| ctrlnum | (OCoLC)907788528 (DE-599)BVBBV037264654 |
| format | Article |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01676naa a2200433 c 4500</leader><controlfield tag="001">BV037264654</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20180830 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">110304s2011 |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)907788528</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV037264654</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-210</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bragesjö, Fredrik</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Dilemmas of a vitalizing vaccine market</subfield><subfield code="b">lessons from the MMR vaccine/autism debate</subfield><subfield code="c">Fredrik Bragesjö and Margareta Hallberg</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2011</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Impfung</subfield><subfield code="0">(DE-588)4026656-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gesundheitspolitik</subfield><subfield code="0">(DE-588)4113743-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Impfschaden</subfield><subfield code="0">(DE-588)4161405-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Impfstoff</subfield><subfield code="0">(DE-588)4026655-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gesellschaft</subfield><subfield code="0">(DE-588)4020588-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Impfung</subfield><subfield code="0">(DE-588)4026656-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Impfstoff</subfield><subfield code="0">(DE-588)4026655-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Impfschaden</subfield><subfield code="0">(DE-588)4161405-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="4"><subfield code="a">Gesundheitspolitik</subfield><subfield code="0">(DE-588)4113743-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="5"><subfield code="a">Gesellschaft</subfield><subfield code="0">(DE-588)4020588-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hallberg, Margareta</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">number:1</subfield><subfield code="g">year:2011</subfield><subfield code="g">pages:107-125</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="t">Science in context</subfield><subfield code="d">Cambridge</subfield><subfield code="g">24 (2011),1, S. [107] - 125</subfield><subfield code="w">(DE-604)BV002714438</subfield><subfield code="x">0269-8897</subfield><subfield code="o">(DE-600)284093-5</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-021177722</subfield></datafield><datafield tag="941" ind1=" " ind2=" "><subfield code="b">24</subfield><subfield code="h">1</subfield><subfield code="j">2011</subfield><subfield code="s">107-125</subfield></datafield></record></collection> |
| id | DE-604.BV037264654 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-09T22:54:46Z |
| institution | BVB |
| issn | 0269-8897 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-021177722 |
| oclc_num | 907788528 |
| open_access_boolean | |
| owner | DE-210 |
| owner_facet | DE-210 |
| publishDate | 2011 |
| publishDateSearch | 2011 |
| publishDateSort | 2011 |
| record_format | marc |
| spelling | Bragesjö, Fredrik Verfasser aut Dilemmas of a vitalizing vaccine market lessons from the MMR vaccine/autism debate Fredrik Bragesjö and Margareta Hallberg 2011 txt rdacontent n rdamedia nc rdacarrier Pharmazeutische Industrie (DE-588)4045696-1 gnd rswk-swf Impfung (DE-588)4026656-4 gnd rswk-swf Gesundheitspolitik (DE-588)4113743-7 gnd rswk-swf Impfschaden (DE-588)4161405-7 gnd rswk-swf Impfstoff (DE-588)4026655-2 gnd rswk-swf Gesellschaft (DE-588)4020588-5 gnd rswk-swf Impfung (DE-588)4026656-4 s Impfstoff (DE-588)4026655-2 s Impfschaden (DE-588)4161405-7 s Pharmazeutische Industrie (DE-588)4045696-1 s Gesundheitspolitik (DE-588)4113743-7 s Gesellschaft (DE-588)4020588-5 s DE-604 Hallberg, Margareta Verfasser aut volume:24 number:1 year:2011 pages:107-125 Science in context Cambridge 24 (2011),1, S. [107] - 125 (DE-604)BV002714438 0269-8897 (DE-600)284093-5 |
| spellingShingle | Bragesjö, Fredrik Hallberg, Margareta Dilemmas of a vitalizing vaccine market lessons from the MMR vaccine/autism debate Pharmazeutische Industrie (DE-588)4045696-1 gnd Impfung (DE-588)4026656-4 gnd Gesundheitspolitik (DE-588)4113743-7 gnd Impfschaden (DE-588)4161405-7 gnd Impfstoff (DE-588)4026655-2 gnd Gesellschaft (DE-588)4020588-5 gnd |
| subject_GND | (DE-588)4045696-1 (DE-588)4026656-4 (DE-588)4113743-7 (DE-588)4161405-7 (DE-588)4026655-2 (DE-588)4020588-5 |
| title | Dilemmas of a vitalizing vaccine market lessons from the MMR vaccine/autism debate |
| title_auth | Dilemmas of a vitalizing vaccine market lessons from the MMR vaccine/autism debate |
| title_exact_search | Dilemmas of a vitalizing vaccine market lessons from the MMR vaccine/autism debate |
| title_full | Dilemmas of a vitalizing vaccine market lessons from the MMR vaccine/autism debate Fredrik Bragesjö and Margareta Hallberg |
| title_fullStr | Dilemmas of a vitalizing vaccine market lessons from the MMR vaccine/autism debate Fredrik Bragesjö and Margareta Hallberg |
| title_full_unstemmed | Dilemmas of a vitalizing vaccine market lessons from the MMR vaccine/autism debate Fredrik Bragesjö and Margareta Hallberg |
| title_short | Dilemmas of a vitalizing vaccine market |
| title_sort | dilemmas of a vitalizing vaccine market lessons from the mmr vaccine autism debate |
| title_sub | lessons from the MMR vaccine/autism debate |
| topic | Pharmazeutische Industrie (DE-588)4045696-1 gnd Impfung (DE-588)4026656-4 gnd Gesundheitspolitik (DE-588)4113743-7 gnd Impfschaden (DE-588)4161405-7 gnd Impfstoff (DE-588)4026655-2 gnd Gesellschaft (DE-588)4020588-5 gnd |
| topic_facet | Pharmazeutische Industrie Impfung Gesundheitspolitik Impfschaden Impfstoff Gesellschaft |
| work_keys_str_mv | AT bragesjofredrik dilemmasofavitalizingvaccinemarketlessonsfromthemmrvaccineautismdebate AT hallbergmargareta dilemmasofavitalizingvaccinemarketlessonsfromthemmrvaccineautismdebate |